New drug MTM-H-001 takes on tough blood cancers
NCT ID NCT07476378
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new drug called MTM-H-001 in 69 adults with B-cell blood cancers (like certain lymphomas and leukemias) that have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors. It's an open-label, single-arm trial, meaning everyone gets the drug and there's no placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MTM-H-001 Injection
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat B-cell blood cancers.
- What could go wrong
- This is a very early, small trial (69 people) with no control group. It mainly checks safety, so it may not show clear benefit or could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Langfang, Hebei, 065000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Tough-to-Treat blood cancers
- Can young lymphoma patients still have kids after chemo? new study follows them for 10 years
- New hope for blood cancer patients: experimental drug takes on standard therapy
- New transplant strategy shows promise for blood cancer relapse
- Can a smart patch predict dangerous immune reactions in cancer treatment?
- 15-Year watch begins for CAR t cell therapy patients